BioMarin Pharma (BMRN) Tops Q3 EPS by 23c; offers guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.46, $0.23 better than the analyst estimate of $0.23. Revenue for the quarter came in at $581.3 million versus the consensus estimate of $607.5 million.

GUIDANCE:

BioMarin Pharma sees FY2023 EPS of $1.90-$2.05, versus the consensus of $2.19. BioMarin Pharma sees FY2023 revenue of $2390-2470 million, versus the consensus of $2449 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Morgan Stanley continues to recommend exposure to the broadening theme
• SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance
• Aqua Capital lifts Energizer (ENR) stake to 7.34M shares as stock trades at 7.9x P/E